Interstitial lung disease, including idiopathic pulmonary fibrosis

(IPF), remains high-risk for drug development, as in-vitro

techniques fail to recapitulate the human in-vivo disease

environment. Xylyx Bio offers custom fibrotic human lung ECM

substrates to significantly improve in-vitro disease modeling and

drug development in a disease-relevant setting. 

Features

Recapitulate human lung fibrosis in vitro

Disease-specific ECM composition

Applicable in 2D and 3D in-vitro models 

Compatible with high-throughput screening 

Xeno-free

IPF tissue

TissueSpec®

IPF Scaffold

αSM

A

TissueSpec® IPF Scaffolds support fibrotic disease-associated phenotype of primary human pulmonary fibroblasts significantly more

consistent with human IPF tissue than cells cultured on plastic. (a) Immunostaining of alpha smooth actin (αSMA). (b) Quantification ofsecreted basic fibroblast growth factor (bFGF) and transforming growth factor beta (TGFβ). Scale bar: 50 µm. * p < 0.05.

IPF-associated phenotype of pulmonary fibroblasts

Human fibrotic lung ECM substrates

The cell environment company xylyxbio.com

Accelerating anti-fibrotic drug development

TissueSpec® ECM Scaffold

TissueSpec® ECM Hydrogel

NativeCoat™ ECM Coating

Organotypic ECM platform for anti-fibrotic drug development

abFGF (secreted)

b

plasticTissueSpec®

IPF Scaffold

TGFβ (secreted)

__plasticTissueSpec®

IPF Scaffold

*

cell-based assays

Lung ECM

Lung ECM products

24

18

12

6

100

90

80

70

pg/m

L

pg/m

L

https://xylyxbio.com/products/cell-culture/

a b

The cell environment company xylyxbio.com

Partner with Xylyx Bio!

We are actively partnering with leading pharmaceutical companies to further develop and integrate our disease-specific ECM

products into cell-based assays and established workflows to accelerate pharmaceutical drug discovery and development.

For partnering opportunities, contact us today at info@xylyxbio.com

Disease-relevant ECM platform for predictive anti-fibrotic drug testing

TissueSpec® IPF Scaffolds are a physiologic human ECM environment for predictive drug testing. (a) Growth curves and (b) relative

expression of COL1A1 by human pulmonary fibroblasts after treatment with an anti-fibrotic drug candidate (PF 3644022).

b

TissueSpec® IPF Scaffolds have a composition and mechanical stiffness consistent with human IPF tissue. (a) Quantification of key ECM

components shows high similarity between TissueSpec® IPF Scaffolds and human IPF tissue. (b) Mechanical stiffness of TissueSpec®

IPF Scaffolds matches IPF tissue. * p < 0.001.

Drug testing

kP

a

IPF

tissue

TissueSpec®

IPF  Scaffold

plastic

Chan

ge

in c

ell num

ber

from

bas

elin

e (%

)

TissueSpec® IPF Scaffolds recapitulate the IPF disease environment

ECM components

collagens elastin

a

Mechanical stiffness

GAG

TissueSpec® IPF Scaffold

IPF tissue*

Time (day)

control

drug (PF 3644022)

TissueSpec® IPF Scaffold

plastic

Rel

ativ

e ex

pre

ssio

n

control drug

COL1A1

µg/m

g

1000

100

10

1

1.0

0.5

0.0

150

125

100

0 2 4 6

https://xylyxbio.com/products/cell-culture/http://xylyxbio.com/

Rel

ativ

e ex

pre

ssio

n 

Xylyx Bio's custom human (normal or fibrotic) liver ECM

substrates recreate the fibrotic liver environment in vitro to

offer a significantly improved disease-relevant setting for

fibrosis modeling and drug development.

Features

Recapitulate human liver fibrosis in vitro

Fibrotic liver ECM composition

Applicable in 2D and 3D in-vitro models 

Compatible with high-throughput screening 

Xeno-free

Platform for modeling fibrotic liver disease

Human fibrotic liver ECM substrates

IN MATRICO® Drug Discovery xylyxbio.com

Accelerating anti-fibrotic drug development

TissueSpec® ECM Scaffold

TissueSpec® ECM Hydrogel

NativeCoat™ ECM Coating

Organotypic ECM platform for anti-fibrotic drug development

cell-based assays

Liver ECM

Normal and Fibrotic Liver ECM substrates

cGene expressionb

1

Cell proliferation

Cel

l num

ber

(10

E4)

100

75

25

1.0

0.5

0.0

50

03 5 7

collagen I coat

Normal Liver ECM Scaffold

Fibrotic Liver ECM Scaffold

ACTA2 COL1A1

Hepatic stellate cells (a) integrate into 3D TissueSpec® Liver ECM Scaffolds and (b) exhibit differential expression of fibrosis-

related genes in liver ECM scaffolds compared to plastic. (c) Cells proliferate over 7 days in normal and fibrotic liver ECM

scaffolds with higher proliferation in fibrotic liver ECM scaffolds, consistent with progressive fibrotic liver disease.

Cell morphologya

pla

stic

Norm

al L

iver

EC

M S

caff

old

_H&E stain trichrome stain

col I coat no ECM

2.0

Time (days)LOXL2

1.5

Normal

Fibrotic

Plastic

Normal + TGFβFibrotic + TGFβPlastic + TGFβ

https://xylyxbio.com/products/cell-culture/

TGFβ (25nM)TGFβ-

We actively partner with leading pharmaceutical companies to integrate products in drug discovery and screening workflows

and develop specialized disease-specific cell-based assays.

For partnering opportunities and any other inquiries contact us today at info@xylyxbio.com

Primary hepatic stellate cells (a) in normal and fibrotic human liver ECM hydrogels. (b) Differential secretion of connective

tissue growth factor (CTGF) in human liver ECM scaffolds after 72 hours. (c) Hepatic stellate cells have more physiologic

gene expression in liver ECM hydrogels compared to other substrates. (d) After treatment with Erlotinib for 72 hours, hepatic

stellate cells in liver ECM hydrogels show greater sensitivity at higher drug concentrations.

Anti-fibrotic compound testing

Characterization of hepatic stellate cells IN MATRICO®

IN MATRICO® Drug Discovery xylyxbio.com

Partner with us!

Primary human hepatic stellate cells

were cultured with or without TGFβ(25nM). Cells show continual

proliferation on plastic but attenuated

proliferation in liver ECM hydrogels

in response to Pirfenidone (2.7mM),

consistent with expected antifibrotic

effect of Pirfenidone.

bCell morphologya CTGF secretion

dGene expressionc Drug response

Cel

l num

ber

(x1

00

0)

Rel

ativ

e ex

pre

ssio

n

Cel

l vi

abili

ty (

%)

CTG

F

(pg/m

L/1

00

0 c

ells

)

120

90

60

30

0.1 101 100Erlotinib (µM)

250

150

50

Normal ECM Fibrotic ECM Plastic

3

2

1

0ACTA2 COL1A1 LOXL2 MMP2

60

40

20

0

60

40

20

0

60

40

20

00 1 2 3 0 1 2 3 0 1 2 3

Time (day)Time (day)Time (day)

Plastic (no ECM) Normal ECM Fibrotic ECM

+Normal ECM Fibrotic ECM

Normal 

Fibrotic 

Plastic 

+- +- +-

350

Vehicle (DMSO) TGFβ Pirfenidone TGFβ + Pirfenidone

Normal

Fibrotic

Plastic

Normal + TGFβFibrotic + TGFβPlastic + TGFβ

http://xylyxbio.com/https://xylyxbio.com/products/cell-culture/